Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study

PURPOSE: Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the efficacy and safety of atezolizumab plus bevacizumab as first-line therapy for advanced mucosal melanoma. PATIENTS AND METHODS: This multice...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Lili, Fang, Meiyu, Chen, Yu, Wei, Xiaoting, Cao, Jun, Lin, Jing, Zhang, Peng, Chen, Ling, Cao, Xiao, Chen, Yujun, Guo, Jun, Si, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623232/
https://www.ncbi.nlm.nih.gov/pubmed/36044526
http://dx.doi.org/10.1158/1078-0432.CCR-22-1528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623232/
https://www.ncbi.nlm.nih.gov/pubmed/36044526
http://dx.doi.org/10.1158/1078-0432.CCR-22-1528

Ejemplares similares